Compare Dyne Therapeutics Inc. Common Stock (DYN) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs US Bancorp — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while US Bancorp trades at $56.5 (market cap $88.64B). The key difference: US Bancorp is far larger — about 31× Dyne Therapeutics Inc. Common Stock's market cap, and US Bancorp pays a 3.8% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and US Bancorp for 98 Days on average.
| DYN | USB | |
|---|---|---|
Market Cap | $2.86B | $88.64B |
Volume | 3,341,579 | 8,200,583 |
Sector | Health | Financials |
52-Week High | $26.78 | $65.42 |
52-Week Low | $14.60 | $45.47 |
Typical Hold Time | 0 Days | 98 Days |
Enterprise Value | $2.18B | $118.14B |
Dividend Yield | — | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
U.S. Bancorp (USB) trades at $56.26, down 2.02% today, with a bearish technical signal from moving averages. The company shows strong fundamentals with a P/E of 11.36 and net income margin of 27.61%, having beaten earnings estimates for three consecutive quarters. Recent news highlights dividend increases and strong Q3 expectations, while analyst consensus remains positive with a $69.94 price target.
USB presents a value opportunity with attractive valuation metrics and consistent earnings outperformance, though near-term technical weakness and regulatory uncertainties pose risks. The stock's 3.8% dividend increase signals management confidence, but investors should monitor interest rate sensitivity and competitive pressures in the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
